Steph
@stephw.bsky.social
🥯 🗽 🇺🇸 🇧🇪
PhD | Bioinformatics, Computational Biology, Genomics, Cancer
PhD | Bioinformatics, Computational Biology, Genomics, Cancer
Happy to share my last paper in JCO PO: Real-World Validation of #PurIST Classifier for Informing Therapy Selection in #PDAC ascopubs.org/doi/full/10....
Only Classical pts benefit from 1L FOLFIRINOX v. GemPac (33% relative risk reduction in death). Basal pts don't.
#PancreaticCancer #Oncology
Only Classical pts benefit from 1L FOLFIRINOX v. GemPac (33% relative risk reduction in death). Basal pts don't.
#PancreaticCancer #Oncology
September 5, 2025 at 12:40 AM
Happy to share my last paper in JCO PO: Real-World Validation of #PurIST Classifier for Informing Therapy Selection in #PDAC ascopubs.org/doi/full/10....
Only Classical pts benefit from 1L FOLFIRINOX v. GemPac (33% relative risk reduction in death). Basal pts don't.
#PancreaticCancer #Oncology
Only Classical pts benefit from 1L FOLFIRINOX v. GemPac (33% relative risk reduction in death). Basal pts don't.
#PancreaticCancer #Oncology